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A B S T R A C T
Non-cholesterol sterols are present in our body at very low concentrations as compared to cholesterol.
Small changes in the structure of sterol molecules confer them highly distinct biological activities. The
best-known example are steroid hormones derived from cholesterol. During the past decade, our
knowledge of also other biomolecules related to or derived from cholesterol, particularly plant sterols,
biosynthetic precursors of cholesterol, and oxysterols, has expanded rapidly. In this review article we
recapitulate the latest insights into the properties and physiological activities of these non-cholesterol
sterols, as well as their importance in disease processes and potential as diagnostic biomarkers.
ã 2015 Elsevier Ltd. All rights reserved.
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Cholesterol is a lipid essential for all mammalian cells, present
at high concentrations in cellular plasma membranes and certain
intracellular organelles, as well as in plasma lipoproteins. It is by
far the most abundant individual lipid molecular species withinAbbreviations: ABC, ATP-binding cassette (transporter); HDL, high-density
lipoproteins; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; LDL, low-
density lipoproteins; LXR, liver X receptor; NPC1L1, Niemann-Pick C1-like 1; VLDL,
very-low-density lipoproteins.
* Corresponding author at: Minerva Foundation Institute for Medical Research,
Biomedicum 2U, Tukholmankatu 8, FI-00290 Helsinki, Finland.
E-mail address: vesa.olkkonen@helsinki.ﬁ (V.M. Olkkonen).
http://dx.doi.org/10.1016/j.jsbmb.2015.12.026
0960-0760/ã 2015 Elsevier Ltd. All rights reserved.our body [1,2]. We obtain cholesterol from two sources, from
nutrition and as synthesised de novo by our cells, particularly
hepatocytes (Fig. 1). Cholesterol in the nutrition is absorbed by
enterocytes, which transfer it into the circulation via mesenteric
lymph, after which it is taken up by the liver as a constituent of
chylomicron remnants. The liver packages the nutritional and the
endogenously synthesised cholesterol into lipoproteins (VLDL and
HDL) that it secretes into the bloodstream. The liver is also the
major organ taking up lipoprotein (VLDL, LDL, HDL) cholesterol and
excretes it into bile ducts as such or after conversion into bile acids
(Figs. 1 and 2).
Cholesterol concentrations in human serum are in the range of
millimoles/liter (mM), but there are also other, so-called
non-cholesterol sterols found in the circulation and in tissues at
Fig. 1. Overview of the transport of cholesterol and non-cholesterol sterols in the
human body. The red arrows depict sterol transport in the blood/lymph and the
green ones in the intestine or bile ducts. Under normal circumstances dietary
cholesterol is efﬁciently absorbed, while the vast majority of plant sterols are
returned into the intestinal lumen. Non-cholesterol sterols appear in the circulation
and tissues at very low concentrations. Plant sterols originate from the diet,
cholesterol precursors mainly from the liver, and oxysterols from the brain, lungs,
liver and other tissues (not shown). (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.).
Fig. 2. Overview of the transport of cholesterol (Chol) and plant sterols (Phyto) in
enterocytes and hepatocytes. Cholesterol and part of the plant sterols in the
nutrition are absorbed into enterocytes via the NPC1L1 transporter, but an efﬁcient
retrograde transport mechanism driven by ABCG5/8 recycles a vast majority of the
plant sterols into the intestinal lumen. Sterols are secreted from enterocytes into
lymph as incorporated in chylomicrons and into bloodstream in HDL, and are taken
up by the liver via lipoprotein receptors. The liver also synthesises cholesterol.
Sterols are partly excreted into bile ducts and partly packaged into VLDL and HDL
particles for secretion into the circulation. VLDL in the circulation is converted via
hydrolysis of constituent lipids into smaller LDL particles, the majority of which are
reinternalized into the liver via LDL receptors. Likewise, the majority of the HDL
produced by the liver and the small intestine returns to the liver. NPC1L1, Niemann-
Pick C1-like protein 1; ABC, ATP-binding cassette transporter; apoB48, apolipopro-
tein-B48; TG, triglyceride; BD, bile duct; LDLR, LDL receptor; LRP, LDL receptor-
related protein; SR-B1, scavenger receptor class B, type 1.
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abundant of these are plant sterols and stanols originating from
plant-derived foodstuffs, biosynthetic precursors of cholesterol,
and oxidised derivatives of cholesterol, oxysterols. A vast majority
of plant sterols in the nutrition remain unabsorbed and are
removed from the body in feces; However, small amounts of these
compounds enter the system (Fig. 1). Also cholesterol precursors
enter into the circulation at low concentrations from tissues,
mainly from the liver. The same holds true for oxysterols, which are
generated in small amounts in many tissues, the most important of
which are the liver, the lungs and the brain (Fig. 1).
Cholesterol precursors and oxysterols are more hydrophilic
than cholesterol. This is why their mobility in cells and capability of
penetrating membranes are markedly higher than of cholesterol,
and their half-life in the system much shorter [3]. The concen-
trations of these molecules therefore vary in a more dynamic
manner than cholesterol, and they can be employed as sensitive
indicators of cholesterol metabolism. In this review we present an
overview of the latest insights into the mechanisms of action of
plant sterols, cholesterol precursors, and oxysterols within out
body, their signiﬁcance in disease processes, and their potential as
diagnostic biomarkers.
1.1. The entry of plant sterols and stanols into circulation is efﬁciently
precluded
The western-type diet contains an average of approximately
300 mg cholesterol per day. In addition, it contains roughly the
same amount of plant sterols (approximately 300 mg/day) and
stanols with a saturated cyclical structure (approximately 50 mg/
day).
The Niemann-Pick C1-like protein 1 (NPC1L1) responsible for
cholesterol absorption in enterocytes also mediates the uptake of
plant sterols and stanols by the intestinal epithelium, but most
likely at a lower efﬁciency than cholesterol [4]. The ABCG5 and
ABCG8 transporters form a membrane-associated pump thatconsumes the energy of ATP to remove plant sterols and stanols
from enterocytes back into the intestinal lumen, so that only 0.5–
2% of plant sterols and 0.04–0.2% of stanols enter the system [5].
ABCG5 and 8 also function at the hepatocyte plasma membrane
domain facing bile ducts, removing the plant sterols that have
entered hepatocytes, into bile and further on to the intestine [6].
Moreover, these ABC transporters pump cholesterol from hep-
atocytes to bile ducts (Fig. 2). Serum plant sterols can be employed
as biomarkers for the rate of intestinal cholesterol absorption and
for diagnostics of sitosterolemia, also denoted as phytosterolemia.
Sitosterolemia is a rare autosomal recessively inherited disease,
in which mutations in the ABCG5 or 8 transporters result in
strongly elevated concentrations of plant sterols and stanols in
serum and tissues [4]. Additionally, this condition involves almost
exclusively hypercholesterolemia due to the function of these
transporter proteins in the routing of cholesterol from hepatocytes
to bile ducts (Fig. 2). In sitosterolemia, the serum concentrations of
plant sterols, the most abundant of which are sitosterol and
campesterol, are typically 0.1–1 mM, i.e. approximately 50-fold
higher than the normal levels. This inherited disorder of lipid
metabolism results in the formation of skin and tendon
xanthomas, structural alterations in erythro- and thrombocytes,
hemolysis, and in some patients in an increased cardiovascular
Fig. 3. Simpliﬁed scheme of cholesterol biosynthesis. The precursors mentioned in
the text are indicated with red, and their structures are depicted. The orange arrows
point to differences in structure as compared to cholesterol. Statins inhibit the
enzyme HMGCoA-reductase in the early part of the biosynthetic pathway. CoA,
coenzyme A; HMG, 3-hydroxy-3-methylglutaryl.approximately 1/1000 of that of
cholesterol. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.).
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any of the above clinical observations (even if serum cholesterol
concentrations are within the normal range). The diagnosis can be
veriﬁed by gas chromatography analysis of serum sterol proﬁle and
investigation of ABCG5 and 8 gene defects [7].
Ever since the ﬁrst sitosterolemia patients were reported in the
1970s, researchers have been wondering whether increased
cardiovascular risk is associated with elevated serum concen-
trations of plant sterols. Some of the patients do present with early
onset atherosclerosis, but for instance in a recent French study on
ﬁve sitosterolemia patients at ages 11–32 years, none of the
subjects were found to suffer from atherosclerotic arterial disease
[8]. The putative association between plant sterols and atherogen-
esis has also been investigated in the normal population. The
results from a number of cross-sectional or prospective studies,
meta-analyses and gene polymorphism studies have been
controversial, ranging from protective effects of plant sterols to
harmful, pro-atherogenic roles of these compounds [9–14]. Since
the serum plant sterol concentrations in the normal population are
suggested by several laboratories to act as biomarkers for
cholesterol absorption [15], it is possible that in those studies in
which plant sterol concentrations correlate with the prevalence of
arterial disease, the actual risk factor is a high efﬁciency of
cholesterol absorption and not the plant sterol itself. To conclude, a
possible role of plant sterols in the development of atherosclerotic
arterial disease is as yet poorly understood. Thus, further research
on this topic is warranted.1.2. Cholesterol precursors reﬂect activity of the sterol biosynthetic
pathway
The cellular cholesterol synthesis takes place via a complicated
chain of reactions involving more than 30 enzymes (Fig. 3). The
synthesis begins at acetyl-coenzyme A and leads through
isoprenoids to cyclical precursors that are further modiﬁed to
the ﬁnal product, cholesterol [16]. A rate-limiting enzyme in the
pathway, 3-hydroxyl-3-methylglutaryl coenzyme A, is the target
inhibited by statins (Fig. 3). Squalene mono-oxygenase, which
oxidises squalene to form the ﬁrst cyclical intermediate in the
pathway, lanosterol, is another enzyme limiting the rate of
cholesterol biosynthesis [17]. Cholesterol precursors (most com-
monly squalene, lathosterol, and desmosterol; Fig. 3) leak from
tissues into the circulation in amounts that correlate positively
with activity of the synthetic pathway. This is why the ratio of the
precursor molecules to cholesterol in serum is used as an indicator
of the activity of the sterol biosynthetic pathway. The concen-
trations of the above three precursors in serum are on the average
(and range) as follows in population based studies: squalene 1.7
(1.2–2.1) mmol/l, lathosterol 10 (2–20) mmol/l, and desmosterol 5
(2–7) mmol/l, i.e. approximately 1/1000 of that of cholesterol [18–
20].
In addition to their roles as biomarkers for cholesterol
synthesis, individual cholesterol precursors have further useful
properties. E.g., serum desmosterol concentration was reported to
be higher in patients with non-alcoholic steatohepatitis than in
subjects with mere hepatic steatosis [21]. Moreover, measuring the
concentrations of 7- and 8-dehydrocholesterol is of use when
suspecting the congenital Smith-Lemli-Opitz syndrome (SLOS).
SLOS caused by mutations in 7-dehydrocholesterol reductase is
characterised by a deﬁciency of cholesterol, high concentrations of
7- and 8-dehydrocholesterol, and developmental anomalies.
The brain is the most cholesterol-rich organ and produces
almost all of its cholesterol endogenously. Desmosterol reaches
very high concentrations (up to 30% of total sterols) during the
development of mammalian brain, suggesting an important and
speciﬁc functional role of this precursor sterol in the development
of the central nervous system [22]. The fact that mother’s milk
contains a lot of desmosterol may also bear relevance in terms of
this hypothesis [23]. The mechanisms underlying the accumula-
tion of desmosterol in the developing brain are not fully
understood. We have suggested that one contributing factor could
be the high level of progesterone during gestation; Progesterone
inhibits post-transcriptionally the enzyme that converts desmos-
terol into cholesterol [22].
Alterations in cholesterol precursors potentially associated
with pathogenesis have been observed in neurodegenerative
disorders, such as Alzheimer’s disease. We observed that serum
concentrations of squalene and lathosterol are signiﬁcantly
reduced in familial Alzheimer’s disease, which may reﬂect a
reduction of hepatic cholesterol biosynthesis [24]. Whether this
also reﬂects decreased production of cholesterol within the
Alzheimer’s disease brain is thus far unclear. In some studies
the use of statins has been reported to act protective of Alzheimer’s
disease. This may, however, associate with other biological
activities of statins than cholesterol lowering [25].
1.3. Oxysterols—regulators of sterol metabolism and biomarkers of
oxidative stress
Oxysterols are oxidised derivatives of cholesterol or by-
products of its biosynthesis [26]. The most abundant oxysterols
arise intracellularly as products of enzymatic cholesterol oxidation,
Fig. 4. Generation of some abundant oxysterols from cholesterol. The species in the top row arise through the action of cholesterol hydroxylases belonging to the cytochrome
P450 family (green). The species at the bottom arise through non-enzymatic oxidation (autoxidation) of cholesterol. Structural differences as compared to cholesterol are
indicated in orange. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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enzymatic oxidation of cholesterol, termed autoxidation.
(Fig. 4). Cholesterol autoxidation products arise upon the
processing of foodstuffs but also within our body in vivo. Oxysterol
concentrations in the serum of healthy subjects are extremely low,
the most abundant species reaching maximally 100 nM (<1/
10000 of the concentration of cholesterol). Of the enzymatically
arising oxysterols, 27-hydroxycholesterol originates from the
lungs [27] and several other tissues while 24(S)-hydroxycholes-
terol in mainly generated in the brain [28,29](Fig. 4). Neurons
extrude cholesterol by converting it to 24(S)-hydroxycholesterol,
also denoted as cerebrosterol, which can be used as a biomarker for
cholesterol egress from the brain [30]. The enzymatic oxysterols
have a number of beneﬁcial biological effects, the most important
of which are mediated by the liver X receptor (LXR) transcription
factors [31]. Activation of LXRs by oxysterols enhances the removal
of cholesterol from macrophage foam cells to HDL, from enter-
ocytes to the intestinal lumen and to HDL particles secreted by
these epithelial cells [32], as well as dampens the expression of
pro-inﬂammatory cytokines and protects cells from apoptosis [31].
Physiological concentrations of enzymatic oxysterols are thus,
according to the current view, considered to act as anti-
atherogenic compounds.
Concentrations of oxysterols in serum may rise under
pathological conditions involving oxidative stress, such as familial
combined hyperlipidemia, atherosclerosis, obesity, insulin resis-
tance, and advanced kidney disease [33,34]. The oxysterols
enriched in these disease states mainly represent products of
non-enzymatic cholesterol oxidation, such as 7b-hydroxycholes-
terol and 7-ketocholesterol (Fig. 4). These oxysterol species can be
considered as markers of oxidative stress. They are also enriched in
pathological tissues, of which atherosclerotic lesions and macro-
phage foam cells are most extensively studied [35]. The oxysterols
accumulating in atherosclerotic plaques are known to enhanceinﬂammatory reactions and to cause cell death, which is believed
to promote formation of the necrotic plaque core and destabiliza-
tion of plaques [35,36]. Of note, elevated concentrations of 7-
ketocholesterol and cholestane-3b,5a,6b-triol are found in
various tissues and in blood plasma of patients with Niemann–
Pick type C disease [37–40]. Gene defects in cholesterol 27-
hydroxylase (CYP27A1) lead to reduced bile acid synthesis with a
compensatory increase in the activity of the rate-limiting enzyme
in bile acid synthesis, cholesterol 7a-hydroxylase. The resulting
disease termed cerebrotendinous xanthomatosis (CTX) is charac-
terized by low levels plasma 27-hydroxycholesterol and accumu-
lation of 7a-hydroxylated bile acid precursors, in particular 7a-
hydroxy-4-cholesten-3-one and its derivative cholestanol [41] as
well as certain oxysterol species [42,43]. Plasma oxysterols can
thus be employed for the diagnosis of the above rare inherited
diseases.
2. Conclusions and future perspectives
Non-cholesterol sterols are detected in our body at very low
concentrations. They can be employed as biomarkers for both of
the major routes through which the body acquires cholesterol,
absorption from the nutrition and endogenous biosynthesis: Plant
sterols, such as sitosterol and campesterol, are employed as
biomarkers for sterol absorption, and cholesterol precursors, such
as lathosterol and desmosterol, as markers of cholesterol synthesis.
Oxysterol species arising via non-enzymatic cholesterol oxidation
reﬂect oxidative stress. In addition, oxysterols arising through
enzymatic oxidation of cholesterol can be employed to estimate
how efﬁciently cholesterol is removed from certain tissues, such as
the brain. However, it is as yet unclear to what extent this
information is useful in designing therapy: e.g., the choice of statin
(inhibition of cholesterol synthesis and enhancement of its hepatic
absorption) vs. ezetimibe therapy (inhibition of cholesterol uptake
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thereof. Descamps et al. [44] recently reviewed the eight major
human trials where cholesterol absorption and synthesis were
analyzed on a large scale using the plasma levels of precursors of
cholesterol and plant sterols. At baseline, the inverse relationship
between cholesterol absorption and synthesis (only examined in
two studies) was found to be weak. On statin treatment, four
studies showed that the changes in cholesterol synthesis and
absorption contributed less than 9% to the variability in cholesterol
response to statin therapy. Moreover, it has not been consistently
demonstrated that good absorbers/bad synthesizers are bad
responders to statin and good responders for ezetimibe. The
authors concluded that, with the exception of a reverse effect of
statin and ezetimibe on cholesterol absorption and synthesis, most
ideas supporting the interplay between these two processes lacked
consistency between the published studies. Thus, the use of the
plasma levels of plant sterols and cholesterol precursors as
markers of cholesterol absorption and synthesis is at present
too limited to deﬁnitively evaluate their value in clinical practice.
Large studies addressing the relationship of cholesterol absorption
and synthesis, their optimal measures, and their usefulness in
patient care are thus warranted and necessary. We believe that
wide spectrum proﬁling of sterols can in the future provide
detailed knowledge of a subject’s sterol metabolism and help in the
diagnosis and design of optimal treatment.
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